Consistency assessment, the latest battle, these generic drugs have won again

Source: sabilan 2018-06-11 has passed the consistency evaluation and will roll the original research drug in one place? Recently, Guangxi pharmaceutical machinery purchase network released the notice on publishing the results of declassification of imitated drugs with the same quality and efficacy as the original research drugs into the direct online purchase quotation (batch 2) ▍ the original research drug was exposed by the quotation of paclitaxel for injection (albumin binding type) of rolled stone drug Ouyi group and pemetrexed disodium for injection of Sichuan Huiyu pharmaceutical The price of several drugs was lower than that of the original imported drugs As early as May 29, Guangxi Provincial Pharmaceutical Machinery Procurement Center published the notice on publishing the results of decryption of direct online purchase quotation of generic drugs with the same quality and efficacy as the original research drugs (batch 1) Some products of famous pharmaceutical enterprises such as Yangzijiang Pharmaceutical Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Co., Ltd and Zhejiang Jingxin Pharmaceutical Co., Ltd passing the consistency evaluation of generic drugs are listed (Note: the above picture is from Guangxi medical equipment procurement center) after the direct Internet connection, it is expected that the generic drugs with consistency evaluation will be officially purchased in Guangxi in a short time At that time, some of the original research drugs will be shaken out The results of the third batch of centralized bidding in Shanghai are the first example On June 7, Shanghai Sunshine pharmaceutical purchasing network released the announcement of the bidding results of the third batch of centralized bidding procurement of Shanghai medical institutions According to the results, in the 21 product specifications publicized in the third batch, almost all multinational pharmaceutical companies were out of the market under the price offensive of generic drugs Except for the winning of the bidding of bisoprolol fumarate tablets (5mg * 10 tablets) and simvastatin tablets (20mg * 10 tablets) of sanders (China) Pharmaceutical Co., Ltd., all of them were domestic generic drugs Pfizer, GSK, AstraZeneca, Merck, Sanofi and other products failed to win the bid Taking rosuvastatin calcium tablet as an example, 12 product specifications, including Zhejiang Jingxin pharmaceutical, Zhejiang Haizheng pharmaceutical, Nanjing Zhengda Tianqing pharmaceutical, Nanjing Xiansheng Dongyuan pharmaceutical, Lunan Beite pharmaceutical, AstraZeneca pharmaceutical, etc., have all participated in the bidding before, among which the products of Jingxin pharmaceutical and Zhengda Tianqing have passed the consistency evaluation, and the final result is that Zhejiang Jingxin won the bid, although Beijing new pharmaceutical won the bid Yiruishuvastatin calcium tablet is in the middle of the price ranking, but it still successfully eliminated the star drug of AstraZeneca, "Keding" According to the analysis of pharmaceutical economic report, more and more high-quality domestic generic pharmaceutical enterprises have launched price shocks on the original research drugs in the bidding procurement, and the domestic generic drugs have the advantage of low price, forcing the imported original research drugs to reduce prices or withdraw ▍ under the guidance of the policy, the outbreak of generic drugs according to the statistics of Cyprian blue, in addition to Shanghai and Guangxi, Zhejiang, Shaanxi, Shanxi, Jiangsu, Liaoning, Jilin, Qinghai and other provinces are also promoting the procurement of varieties passing the consistency evaluation According to the requirements of the general office of the State Council, a number of notices have been issued to encourage medical institutions to purchase and use varieties that have passed the conformity assessment Among them, many provinces have issued policies to protect generic drugs Take Zhejiang Province for example On May 9, Zhejiang medical equipment procurement center issued the notice on direct online procurement of generic drugs through the consistency evaluation of quality and efficacy Zhejiang's notice puts forward five advantages for generic drugs that have passed the consistency evaluation: directly linked to the Internet; hospitals give priority to purchase and use; if the negotiation fails to be concluded due to price reasons, another negotiation can be carried out; one product and two regulations can be broken; more than three of the same varieties have passed the consistency evaluation, and the bidding varieties that have failed to pass the evaluation should be suspended In addition to Zhejiang, there are also provinces that propose to purchase the varieties that fail to pass the consistency evaluation, whose price shall not be higher than that of the varieties that pass the consistency evaluation; the varieties that pass the consistency evaluation, enjoy the same treatment as the original research drugs, etc The general office of the State Council issued the opinions on reforming and improving the supply guarantee and use policy of generic drugs on April 3, which is more clear: equal treatment The centralized drug purchase organization shall prepare the purchase catalogue according to the general name of the drug Promote equal competition between generic drugs and original drugs with the same quality and efficacy as the original drugs Promote alternative use of generic drugs The generic drugs that are consistent with the quality and efficacy of the original research drugs shall be included in the catalogue of substitutable drugs with the original research drugs, marked in the instruction manual and label, and relevant information shall be released to the society in time, so as to facilitate the selection and use of medical staff and patients The payment standard of medical insurance is the same Give full play to the incentive role of basic medical insurance We will accelerate the development of payment standards for medical insurance drugs, and pay for generic drugs and original research drugs with the same quality and efficacy as the original research drugs From the above policy orientation, it can be predicted that high-quality generic drugs will usher in the spring, and changes are taking place.